Figure 6.

Baricitinib causes a CD4+ T cell phenotype shift by inhibiting the JAK/STAT pathway. (A) Representative flow cytometry plots show naive CD4+ T cells from the spleens were purified with magnetic microbeads, producing a purity of ≈95%. (B) Ratio of p‐JAK and p‐STAT to total JAK and STAT protein. Purified CD4+ T cells isolated from vehicle or baricitinib-treated EAE mice were restimulated with MOG 35-55 peptide (10 μg/mL). Western blot analysis of phosphorylated and total JAK1, JAK2, STAT1, STAT3, and STAT4 proteins were detected by immune-blotting. Total JAK1, JAK2, STAT1, STAT3, STAT4, and β-actin proteins as loading control were detected by immunoblotting. Quantitative data are the mean ± SEM. *p < 0.05; n = 6 per group. SEM, standard error of the mean.